Data-Gouv-ML/pcri-informations-sur-les-projets-laureats huggingface dataset:
Recollected: History, Memory and Imagination in Contemporary Greek Comics and Graphic Novels (ReCOLLECTED)

Framework: Horizon Europe — Excellent Science
Programme: Marie Skłodowska-Curie Actions (MSCA)
Theme: Marie Skłodowska-Curie
Destination: Postdoctoral Fellowships
Action type: Marie Skłodowska-Curie actions
Panel: Social Sciences and Humanities
Countries involved: Netherlands
Call: MSCA Postdoctoral Fellowships 2021 (HORIZON-MSCA-2021-PF-01, 2021)
Start date: 2023-01-09
End date: 2025-01-08
Duration (months): 24.0
Total project cost (EUR): 187624.32
EU funding (EUR): 187624.32
Participants: 1
Project status: CLOSED

Approaching Greek graphic novels as a site for both artistic innovation and social critique, ReCOLLECTED sheds light on ways in which comics can inform our views on present-day cultural landscapes and engage with broader social issues pertaining to the role of popular culture and cultural heritage in shaping identity and redrawing the boundaries of national belonging. The aim of the project is two-fold. Firstly, it aims to assess what led to the boom of comics in the Greek cultural field over the past decade and identify any shared patterns and characteristics of these comics. Secondly, the project will then use this data to propose categories and conceptual tools that comics can offer for cultivating alternative visions for tackling contemporary problems. In order to reach these aims, ReCOLLECTED relies on an interdisciplinary methodology, combining tools and insights from comics studies with anthropology, cultural analysis, data visualization. The project will develop in close collaboration with comics artists themselves in order to integrate their own perspectives into the framework and in hope to spur debate in the field as well as new directions in comics practice as a result of this collaborative effort. Skills and training gained at UvA in advanced methods for combining ethnographic data and close-reading of cultural texts, conducting interviews and data visualization will ensure that the project contributes to cultural innovation within Greece as well as responds to the latest developments within the transnational field of comics studies.

Keywords: comics and graphic novels,cultural analysis,greek crisis,popular culture
Joining the Dots on Gender Based Violence (PersonalAndPolitical)

Framework: Horizon Europe — Excellent Science
Programme: European Research Council (ERC)
Theme: European research council
Destination: Public Engagement with Research Award
Action type: Recognition Prize
Countries involved: Ireland
Call: ERC-2024-PERA (ERC-2024-PERA, 2024)
Total project cost (EUR): 0.0
EU funding (EUR): 0.0
Participants: 1
Project status: SIGNED

In this prize application, I outline a programme of public engagement that exposed the shared and social nature of gender-based violence, a trauma that is often constructed as personal and even intimate. With my team and collaborators, I have shown how the risk of gender-based violence is central to women’s social identities, how women understand their place and position in society. Our research has shown that being cognizant of this risk has public health implications in terms of mental and physical health for women. My work also demonstrates that understanding violence against women as random and sporadic is part of the problem. Because men do not face the same risk of gender-based violence, men can find it difficult to understand this risk. My work also shows the identity-based threat men face when it is made clear that it is almost always men who perpetrate this violence against women and children. As a consequence, prevailing narratives can construct violence against women as a ‘women’s issue’. Following the murder of a young woman in Ireland, I engaged in a major program of public engagement to counter this narrative. I highlighted the systemic and patterned nature of men’s violence against women through writing and speaking with mainstream media outlets and full engagement with NGO’s and journalists. This promoted a deeper understanding of gender-based violence in Ireland and ultimately facilitated the establishment of a statutory agency dedicated to collectively tackling all forms of gender-based violence (Cuan). I also used our model to evidence whether a group-based intervention could counter the isolation and disconnection felt by women traumatized by domestic violence. Emphasizing the shared nature of the trauma allowed vulnerable women to gains in their health’. This a partnership has been rewarded by an invitation to become a voluntary member of the board of trustees of the service provider to develop their service into the future.

Keywords: trauma gender based violence group supports,policy change
Smart on-board processing for earth observation systems (SOPHOS)

Framework: Horizon Europe — Global Challenges and European Industrial Competitiveness
Programme: Digital, Industry and Space
Theme: Space
Destination: Open Strategic Autonomy in Developing, Deploying and Using Global Space-Based Infrastructures, Services, Applications and Data
Action type: Innovation actions
Countries involved: Germany,Greece,Sweden
Call: End-to-end Earth observation systems and associated services (HORIZON-CL4-2022-SPACE-01, 2022)
Start date: 2022-11-01
End date: 2026-02-28
Duration (months): 40.0
Total project cost (EUR): 2617563.75
EU funding (EUR): 2055006.25
Participants: 5
Project status: SIGNED

The number of satellites being launched into orbit is increasing rapidly every year, and with it the complexity anThe number of satellites being launched into orbit is increasing rapidly every year, and with it the complexity and capabilities of each satellite continues to grow dramatically. Today, near full earth coverage by optical sensors is achieved daily by civilian spacecraft, and soon civilian SAR will achieve a similar daily coverage. The ever growing amount of spaceborne data will need new solutions to get that data to the ground, because the available downlink is always a limitation in space system design. Better on-board data processing and storage will allow future iterations of spacecraft to achieve higher performance in smaller and smaller packages. Current solutions present limitations in computational performance, memory capacity and performance, and data reliability in very small form factors. SOPHOS will design and implement enabling technology for high-end data products produced on-board spacecraft via the implementation of more power efficient high performance space processing chains for various Low-Earth Orbit (LEO) missions, with a focus on Synthetic Aperture Radar (SAR), which is one of the most data intensive space applications currently used. This implementation will be achieved through the optimisation of the payload processing and data storage system accompanied by the use of COTS components and the miniaturisation of high-performance hardware in combination with robust firmware and software with heritage in high-end space applications. SOPHOS will combine state-of-the-art industrial computing technologies (COTS) including high-end FPGAs and GPU equipped SoCs, along with advanced and scalable processing capabilities. The modules developed within SOPHOS will allow for higher data product performance in small and nanosatellite platforms, with the ability to deliver more data from data-intensive applications including SAR earth observation.

Keywords: earth observation,satellite,cots,new space,sar,payload processing,mass memory,ground control,algorithms
Microglia-synapse molecular interactions in neurodegenerative disorders (MicroSyn-MIND)

Framework: Horizon Europe — Excellent Science
Programme: Marie Skłodowska-Curie Actions (MSCA)
Theme: Marie Skłodowska-Curie
Destination: Postdoctoral Fellowships
Action type: Marie Skłodowska-Curie actions
Panel: Life Sciences
Countries involved: Belgium
Call: MSCA Postdoctoral Fellowships 2021 (HORIZON-MSCA-2021-PF-01, 2021)
Start date: 2022-08-01
End date: 2024-07-31
Duration (months): 24.0
Total project cost (EUR): 191760.0
EU funding (EUR): 191760.0
Participants: 1
Project status: CLOSED

Microglia are immune cells that monitor our brain and degrade unhealthy neurons and excess synapses. In Alzheimer’s disease (AD) however, microglia excessively destroy synapses, marking them as enticing treatment targets. AD patients accumulate cortical Amyloid-beta (Aβ) plaques and neurofibrillary tau tangles, whilst losing neurons and synapses, and consequently: memory and cognition. Microglia are the brain’s immune cells, mediate neuroinflammation, continuously monitor their surrounding cells, and prune (eliminate) excess synapses during development. Interestingly, various AD risk genes are highly expressed in- or linked to- microglia, and while “activated” microglia can clear Aβ, they also degrade neurons and synapses. Our knowledge on microglia function mainly stems from rodent studies, which show microglia can target synapses via complement molecules or fractalkine, but we do not know exactly which proteins mediate this contact, how this translates to humans, and how this is affected in AD. I hypothesize that microglia use different cell surface proteins to interact with synapses in AD, compared to a healthy brain. By combining several cutting-edge technologies, I can now test this hypothesis in living, human microglia. I will transplant human iPSC-derived microglial progenitors into the cortex of healthy- and APPNLGF mice, to ensure the microglia develop a transcriptional- and morphological state like human in vivo microglia (expertise of the Mancuso lab). Using TurboID proximity labeling and quantitative high-resolution mass spectrometry, I will tag-, extract-, and identify the proteins at the microglia-synapse interaction site and determine how they differ from the AD mouse model (expertise of the De Wit lab). Given that abnormal microglial function is linked to various neurodegenerative diseases, my work will both provide valuable fundamental knowledge on microglial-synapse interactions and contribute to the development of new AD treatment targets.

Keywords: microglia synapse neurodegeneration alzheimer turboid interactome protein crispr
BABOTS: The design and control of small swarming biological animal robots (BABOTS)

Framework: Horizon Europe — Innovative Europe
Programme: The European Innovation Council (EIC)
Theme: EIC Pathfinder
Destination: Open to supporting projects in all areas of science, technology,...
Action type: EIC actions
Countries involved: Belgium,Israel,Italy,Germany,Finland
Call: EIC Pathfinder Open 2022 (HORIZON-EIC-2022-PATHFINDEROPEN-01, 2022)
Start date: 2023-10-01
End date: 2027-09-30
Duration (months): 48.0
Total project cost (EUR): 3251081.25
EU funding (EUR): 3251081.0
Participants: 6
Project status: SIGNED

We aim to establish a fundamentally new technology of Biological Animal roBots (BABots), consisting of small animals with a genetically modified nervous system, enabling the execution of a desired repertoire of behaviors beyond their natural abilities. We will implement the first BABot system in C. elegans, a 1 mm long nematode worm. These worms will be programmed to act as a collective, and to detect, locate and attack invading pathogens in an agricultural setting. Being 100% biological, BABots are highly compatible with the natural environment, self-producible, and fully degradable. They will also be agile and highly sensitive to surrounding signals. To control BABot behavior, we will genetically insert specific new synaptic connections and synthetic gene circuits in C. elegans to produce artificial aggregation, dynamic sensorimotor switching and other functional building blocks. To ensure a safe and controlled deployment, we will genetically implement a multi-layered biocontainment apparatus. To gain tighter control over the BABot collective behavior, we will exploit heterogeneity in the population, blending, for example, leader and follower BABots, based on their differential access to information. The science behind this innovative technology includes a synthetic neurobiological approach to modifying individual worm behavior, the study of collective behavior in engineered worms, and the development of a theory of heterogeneity-based swarm control. We also dedicate a substantial effort to establish a firm and effective safety, ethical and regulatory framework, under which current and future BABots can be developed. This project will generate a radically new approach to bio-robotics that could contribute to precision agriculture, industry and medicine. Improving over a previous proposal, we significantly enhanced (i) the methodology, (ii) the safety and ethical aspects, and (iii) the demonstration and exploitation by implementation in an agricultural setting.

Keywords: c elegans,swarm intelligence,ethics of new emerging technologies,odor sensation
Clinical validation of an antibiotic-resistant bacteria global vaccine platform through the first vaccine against Klebsiella pneumoniae (K-VAX)

Framework: Horizon Europe — Innovative Europe
Programme: The European Innovation Council (EIC)
Theme: EIC Accelerator
Destination: Open to supporting projects in all areas of science, technology,...
Action type: EIC actions
Countries involved: Spain
Call: EIC Accelerator Open 2024 (HORIZON-EIC-2024-ACCELERATOR-02, 2024)
Start date: 2025-01-01
End date: 2026-12-31
Duration (months): 24.0
Total project cost (EUR): 3563927.13
EU funding (EUR): 2494748.99
Participants: 1
Project status: SIGNED

VAXDYN, a Spanish biotech startup, is leading innovation with a novel vaccine platform targeting antimicrobial-resistant (AMR) infections, a critical global health threat. With projections indicating a potential cost of USD 100 trillion and over 10 million deaths by 2050 due to AMR, VAXDYN's work is of paramount importance. Their patented technology focuses on the most dangerous AMR bacteria, developing vaccines for four out of the six most urgent bacterial pathogens, which are responsible for 73% of AMR-related deaths worldwide. VAXDYN's vaccine platform stands out for its utilization of full Outer-Membrane Protein bacterial antigens with a safe carrier cell to stimulate immunity. This unique strategy has earned approval from European regulators and prestigious backers such as the CARB-X accelerator, funded by entities including the Bill and Melinda Gates Foundation and the Wellcome Trust. The company's lead vaccine, K-VAX, targets Klebsiella pneumoniae, the third leading cause of AMR deaths, claiming 700,000 lives annually. There are no current vaccines against this pathogen, which has a mortality rate exceeding 50%. VAXDYN's K-VAX aims to serve both the global elderly population and prevent neonatal sepsis in low-and middle-income countries, addressing a potential $6 billion market by 2035. VAXDYN is advancing K-VAX through Phase 1A trials, supported by CARB-X and private investors. The next steps involve Phase 1B and Phase 2 trials to determine the final formulation and efficacy, for which EIC funds are crucial. Post-trials, VAXDYN plans to license K-VAX, continuing the development of its second vaccine, P-VAX, for Pseudomonas aeruginosa infections in patients with chronic respiratory conditions. This strategic move underscores VAXDYN's commitment to addressing urgent health crises and leading in the AMR vaccine domain.

Keywords: vaccine klebsiella pneumoniae amr antimicrobial resistance antibacterial resistance antibiotic resistance
ATHLETIC - Anocca THe Leading European T-cell Immunotherapy Company (ATHLETIC)

Framework: Horizon Europe — Innovative Europe
Programme: The European Innovation Council (EIC)
Theme: EIC Accelerator
Destination: Other destinations
Action type: EIC actions
Countries involved: Sweden
Call: EIC Accelerator 2024 - Short application (HORIZON-EIC-2024-ACCELERATOR-01, 2024)
Duration (months): 18.0
Total project cost (EUR): 17500000.0
EU funding (EUR): 17500000.0
Participants: 1
Project status: SIGNED

Anocca is at the forefront of unlocking the potential of T cell immunity to lead the fight against cancer and other serious diseases. The company was created to vastly expand the availability of truly transformative T cell therapies to patients that have limited alternatives today. The initial focus is to develop T cell receptor (TCR) modified T cell therapies (TCR-T) for untreatable cancers and then expand into infectious and autoimmune disease where T cell immunotherapies have the potential to provide novel curative treatment options. The company has built a unique deep-tech discovery platform to decipher T cell biology which allows precise, rapid and cost-effective development of broad libraries of precision TCR-T cell therapies. To date, Anocca has already built the broadest and fastest growing pre-clinical oncology pipeline covering a wide range of hard-to-treat solid tumour indications in broad patient populations. The company is currently progressing the first assets from its broad pipeline into clinical development and will shortly launch a differentiated multi-asset clinical program targeting KRAS mutations in pancreatic cancer. With a unique advanced R&D platform, the largest GMP certified cell-therapy manufacturing facility in the Nordics, access to advanced manufacturing technologies and an in-house clinical operations team, Anocca has the end-to-end capability to independently bring product candidates from discovery through clinical development. Anocca is starting this with targeting KRAS mutations in pancreatic cancer, with many more therapies and clinical programs to follow. Anocca is a privately held biotechnology company with over 110 highly skilled employees working out of state-of-the-art facilities in Sweden. To date, Anocca has raised a total of €140m incl. a €25m EIB Venture Debt Facility. Anocca is now seeking additional capital to finance its first clinical program and continue to expand its pipeline of transformative TCR-T cell therapies.

Keywords: immunotherapy,t cell therapy,tcr t,discovery platform,gmp manufacturing,clinical development,oncology,infectious disease,autoimmune disease,autologous,allogeneic,clinical trial
The first and best-in-class treatments for rare and severe genetic skin diseases (DERMA-CURE)

Framework: Horizon Europe — Innovative Europe
Programme: The European Innovation Council (EIC)
Theme: EIC Accelerator
Destination: Other destinations
Action type: EIC actions
Countries involved: Israel
Call: EIC Accelerator 2024 - Short application (HORIZON-EIC-2024-ACCELERATOR-01, 2024)
Duration (months): 24.0
Total project cost (EUR): 2490000.0
EU funding (EUR): 2490000.0
Participants: 1
Project status: SIGNED

Kamari Pharma (KP) is dedicated to developing first-in-class drugs to treat rare dermatologic conditions such as keratoderma and ichthyosis. KP aims to address this unmet medical need by providing effective therapies for these neglected patients. Unlike existing treatments that offer only mild symptomatic relief, KP is developing new chemical entities targeting a key mechanism (TRPV3 inhibition) involved in these conditions. This approach promises to restore skin health, improve quality of life, and address these otherwise incurable pathologies. Clinical data on KP's proprietary topical TRPV3 inhibitor, KM-001, demonstrates the potential of this drug class in offering effective and safe treatment for mild cases of keratoderma and ichthyosis, with significant safety. KP is also completing preclinical development of another TRPV3 inhibitor, KM-023. KM-023 aims to provide systemic benefits, treating the most severe and life-threatening conditions of keratoderma and ichthyosis. Beyond medical benefits, keratoderma and ichthyosis patients will experience improved quality of life, including increased self-esteem, more outdoor activities, and economic benefits such as rejoining the workforce and gaining financial independence. KP's team combines scientific and business expertise to translate therapies for orphan diseases. Supported by a strong board of directors and medical advisors, KP is engaging with patient advocacy groups. These factors position KP for rapid market penetration following regulatory approval of KM-001 and KM-023. EIC funding is crucial to finalize the preclinical development of KM-023 and initiate its clinical validation. The total addressable market for KM-023 is $51.2B, covering 512,000 patients globally. The Serviceable Available Market is $13.89B with 138,900 patients in major markets. A 50% penetration rate results in a Serviceable Obtainable Market of $6.2B in 2031.

Keywords: rare dermatologic conditions,severe life threatening skin conditions,genetic skin diseases,orphan drug,keratoderma,ichthyosis,trpv3 inhibition,dermatology,quality of life
High-Quality Graphene Supports for Microspectroscopic Techniques. (HYPERGRAPH)

Framework: Horizon Europe — Excellent Science
Programme: European Research Council (ERC)
Theme: European research council
Destination: Proof of concept grants
Action type: ERC actions
Countries involved: Belgium
Call: ERC PROOF OF CONCEPT GRANTS1 (ERC-2022-POC1, 2022)
Start date: 2023-08-01
End date: 2025-01-31
Duration (months): 18.0
Total project cost (EUR): 150000.0
EU funding (EUR): 150000.0
Participants: 1
Project status: CLOSED

Transmission electron microscopy (TEM) is a powerful technique to fully characterise the local structure of a broad range of materials. Due to many recent hardware advances, the quality of TEM measurements is nowadays ultimately determined by the sample supports. Surprisingly though, their importance has been majorly overlooked so far. The many benefits of graphene layers as a support have been well-recognised by the community, but commercial “graphene grids” show poor coverage and are dominated by unwanted residues and Cu nanoparticles from the preparation process. Consequently, commercial graphene grids currently correspond to merely 1% of the grids used. A solution to this problem is a novel protocol to produce high-quality graphene grids, developed within my ongoing ERC Consolidator grant “REALNANO”. A head-to-head comparison with the state-of-the-art demonstrates the superior quality of the HYPERGRAPH grids. Moreover, our ongoing market survey with leading groups in both materials and life science indicates a very strong need for graphene grids that yield high and constant quality. Therefore, the overall aim of this PoC is to deliver our HYPERGRAPH supports to the TEM community, our beachhead market. To reach this goal, our methodology is based on further product development (reproducibility, cost-efficiency and shelf-life), exploration of other possible applications and business planning. In this manner, we aim to increase the Technology Readiness Level for HYPERGRAPH from 4 to 7 and the and Commercial Readiness Level from 4 to 6. Feeling the “pain” related to the poor quality of TEM supports as an end user every day, I am convinced that valorisation of our technology can fill a crucial void in the TEM value chain. In this manner, HYPERGRAPH will enable characterisation and further development of new generations of nano- and biomaterials, with applications in fields as broad as catalysis, medicine, protein research, viral infections and energy.